Share this article
SALT LAKE CITY, Feb. 16, 2021 /PRNewswire/ Co-Diagnostics, Inc.
(Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it will be presenting on direct saliva testing for COVID-19 at the 28
th Annual International Molecular Medicine Tri-Conference, held virtually on February 16-18, 2021.
Company representatives will introduce the Co-Diagnostics Logix Smart SARS-CoV-2 DS (Direct Saliva) kit, which the Company has submitted for Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA). The virtual presentation will be webcast to conference attendees at 4:30 pm EST on Tuesday February 16